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Abstract
Objective: To perform a systematic review, and if possible a meta-analysis, to establish whether depressed patients with co-
morbid chronic somatic illnesses are a high risk ‘‘double trouble’’ group for depressive recurrence.
Method: The databases PubMed, EMbase and PsycINFO were systematically searched until the 4th of December 2012 by
using MeSH and free text terms. Additionally, reference lists of retrieved publications and treatment guidelines were
reviewed, and experts were consulted. Inclusion criteria were: depression had to be measured at least twice during the
study with qualified instruments and the chronic somatic illness had to be assessed by self-report or by a medical
professional. Information on depressive recurrence was extracted and additionally risk ratios of recurrence were calculated.
Results: The search generated four articles that fulfilled our inclusion criteria. These studies showed no differences in
recurrence over one- two- three- and 6.5 years of follow-up for a total of 2010 depressed patients of which 694 patients
with a co-morbid chronic somatic illness versus 1316 patients without (Study 1: RR = 0.49, 95% CI, 0.17–1.41 at one year
follow-up and RR= 1.37, 95% CI, 0.78–2.41 at two year follow-up; Study 2: RR = 0.94, 95% CI, 0.65–1.36 at two year follow-up;
Study 3: RR = 1.15, 95% CI, 0.40–3.27 at one year follow-up; RR= 1.07, 95% CI, 0.48–2.42 at two year follow-up and RR= 0.99,
95% CI,0.55–1.77 at 6.5 years follow-up; Study 4: RR = 1.16, 95% CI, 0.86–1.57 at three year follow-up).
Conclusion: We found no association between a heightened risk for depressive recurrence and co-morbid chronic somatic
illnesses. There is a need for more longitudinal studies to justify the current specific treatment advice such as long-term
pharmacological maintenance treatment for this presumed ‘‘double trouble’’ group.
Citation: Kok GD, Bockting CLH, Burger H, Hannig W, Pijnenborg GHM, et al. (2013) Double Trouble: Does Co-Morbid Chronic Somatic Illness Increase Risk for
Recurrence in Depression? A Systematic Review. PLoS ONE 8(3): e57510. doi:10.1371/journal.pone.0057510
Editor: Jerson Laks, Federal University of Rio de Janeiro, Brazil
Received December 11, 2012; Accepted January 22, 2013; Published March 5, 2013
Copyright:  2013 Kok et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: c.l.h.bockting@rug.nl
Introduction
Major Depressive Disorder (MDD) has a highly recurrent
nature [1] with relapse and recurrence rates rising up to 85% [2].
Recurrence is defined as a new Major Depressive Episode (MDE)
after recovery, that is at least six months without meeting full
MDE criteria, whereas relapse is the return of a MDE during
remission but before recovery (1988, MacArthur Foundation
Research Network on the Psychobiology of Depression) [3].
Most frequently used international evidence based clinical
practice guidelines i.e. National Institute for Health & Clinical
Excellence (NICE) [4], [5], American Psychiatric Association
(APA) [6], presume that co-morbid chronic general somatic
disorders are associated with poorer outcomes of depression
including an increased risk of recurrence (for readability we always
refer to recurrence in case of relapse or recurrence).
Depression is more prevalent in people suffering somatic illness,
with prevalence rates being two [7] to even three times as high as
for people without somatic illness [6], [8]. Depression has been
associated with poorer outcomes of somatic illness [5], [8–10], in
terms of more functional disability, higher care consumption and a
lower quality of life [11]. Conversely, the presence of a co-morbid
chronic somatic condition is perceived as an ongoing stressor that
predisposes patients to depressive episodes [6]. The APA [6]
describes ‘‘the presence of a chronic general medical disorder’’ as a
risk factor for recurrence of MDD and therefore recommends that
‘‘some form of maintenance treatment will be required indefinite-
ly’’.
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Objectives
Remarkably, there are no reviews or meta-analyses that
examined the effect of co-morbid chronic somatic illness on
depressive recurrence. Given the impact of current international
clinical guidelines, we aim to systematically review the evidence as
to whether somatic illness is a risk factor for recurrences of MDD
over a period of at least six months. If possible a meta-analysis will
be performed as well (depending on the number of studies and
their methodological characteristics).
Methods
Inclusion criteria
Inclusion criteria for our review were: (1) longitudinal measure-
ment of the course of depression (2) providing absolute numbers or
percentages of recurrence a) diagnosis established with an
interview based on state- of the- art depression criteria (e.g.
Diagnostic and Statistical Manual of Mental Disorders, DSM-III/
III-R/DSM-IV) [12–14] or b) with standardized questionnaires
that assess depressive symptoms (e.g., Inventory of Depressive
Symptomatology, IDS) [15] or -, Hamilton Rating Scale for
Depression, HRSD) [16] (3) with a follow-up of at least six months
(4) in which data were collected for patients with and without a
certain co-morbid chronic somatic illness at the same measure-
ment intervals a) where co-morbid chronic somatic illnesses were
assessed either via self-report or b) medical records or c) by a
diagnosis of a medical professional. There is great overlap between
self-report of somatic illnesses and diagnoses of these illnesses [17],
therefore studies that used self-report as a measurement tool were
included as well. If treatment effects were studied within a
randomized controlled trial without a treatment-as-usual group,
these were excluded. We also excluded studies on bipolar
disorders. All relevant publications in English, Dutch, Spanish,
Polish or German were taken into account. To assess eligibility of
articles, one reviewer (GK) made the first selection based on titles.
In case of doubt abstracts or full text articles were retrieved for
closer reading. Thereafter, two independent reviewers made a
selection based on abstracts (GK and WH); further winnowing was
performed by two reviewers (GK and CB) based on full text
articles. In case of inconsistencies, articles were evaluated again
until consensus was reached. The kappa statistic for inter-observer
variability was reported for the abstract and full-text selection.
Literature search
In line with the APA [6] and NICE [4], [5] treatment guidelines
we limited the search to chronic somatic illnesses. The chronic
somatic illnesses chosen for this systematic review were: heart
diseases, gastrointestinal diseases, diabetes mellitus, rheumatoid
arthritis, asthma, Human Immunodeficiency Virus (HIV) and
neoplasms. The choice of these chronic somatic illnesses was based
on them being mentioned in the clinical practice guidelines of the
APA [6] and NICE [4] and their high prevalence rates brought up
in additional literature [18], [19].
A combination of MeSH-terms and free text words was entered
into the search engines PubMed, EMbase and PsycINFO. These
were all screened for relevant articles through 4 December 2012.
The terms ‘depression or depressive disorder or major depression
were combined with heart diseases or gastrointestinal diseases or
diabetes mellitus or arthritis, rheumatoid or asthma or HIV or
neoplasms and incidence or follow-up studies or prognos* or
predict* or course or outcome or relaps* or recur* or remis* or
epidemiology. The key words regarding depression outcomes were
based on Altman [20] (box 2) and modified by adding relaps*,
recur* and remis* to fit our research purpose. Since not all studies
might explicitly mention recurrence, even though they studied the
impact on for example chronicity, including recurrence, we
decided on the above mentioned broad search terms. Additionally,
reference lists from included articles, earlier reviews and NICE [4],
[5] and APA [6] clinical treatment guidelines were screened for
other potentially eligible papers and experts were consulted to
identify additional important papers.
Data extraction and outcomes
The following data were extracted from the included articles:
study site, number of participants, their age and gender
distribution, information about depression assessment (method
and measurement intervals), characteristics of the chronic somatic
illnesses (type and assessment method) and the outcome measure
(recurrence). Outcomes consisted of the differences in percentages
or mean numbers of recurrence during follow-up, if applicable for
multiple time intervals, between patients with and without co-
morbid chronic somatic illness. Risk ratios (RR) and 95%
Confidence Intervals (CI) were calculated by using Review
Manager 5.1.
Quality assessment
To allow for judgments on the quality of the included articles
regarding their selection process, design, analyses and outcome
measures, a modified version of the Newcastle-Ottowa Quality
Assessment Scale for cohort studies was used [21]. This instrument
was reviewed by Deeks et al. [22] and described as one of the most
usable methods for this type of study [22], [23]. All articles were
judged by two reviewers (GK and WH). If information on a
quality criterion was not mentioned explicitly in the article, we
assigned a question mark.
Results
Study selection
As shown in figure 1, the search engines yielded 3450 articles in
total. Twenty records were identified via additional sources
including APA guidelines (n = 6), experts (n = 2), reference lists
from subsequently included articles (n = 10), and important
reviews (n = 2). After screening based on title done by one
reviewer (GK), 3121 articles were excluded. Main reasons for
exclusion based on title were: studies reported about the influence
of depression in a somatic illness population only or about the
prevalence of depression only. A total of 349 abstracts subse-
quently were screened by two independent reviewers (GK and
WH). After removal of 55 duplicate titles, eventually 51 full text
articles were retrieved for close reading. Detailed information on
reasons for exclusion is shown in the flow diagram (figure 1).
Finally, four articles about recurrence of depression in patients
with and without co-morbid chronic somatic illness were included.
The Kappa statistic for the inter-observer variability was 0.91.
Data extraction from included studies
Data were extracted for the four articles with a total number of
2010 patients (n = 554 in study 1, n = 715 in study 2, n = 54 in
study 3, and n= 687 in study 4) yielding information on 694
patients (34.5%) who suffered one or more chronic somatic illness.
Table 1 gives an overview of the data extracted from the four
studies.
Study characteristics
Study 1: A non-experimental longitudinal follow-up study by
Wells, Rogers, Burnam, and Camp [24] with adults who received
care in one of the following settings: ‘‘large group-practice-style
Risk for Depressive Recurrence in Somatically Ill
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Figure 1. Flow chart of the study selection.
doi:10.1371/journal.pone.0057510.g001
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health maintenance organizations (HMOs), large multispecialty
mixed prepaid and fee-for-service group practices, and small
single-specialty group and solo practices’’. Patients with either a
current depressive disorder or depressive symptoms where
included (n = 554 patients). A depressive disorder was defined as
meeting DSM-III criteria [12] for a lifetime diagnosis of MDD or
dysthymia, an episode of MDD or dysthymia during the past 12
months, with no remission since the onset of the recent episode.
Depressive symptoms were present when the cut-off score on a
brief depression screener was exceeded [25]. According to the
authors (personal communication), patients were asked how many
episodes they experienced over follow-up with at least a two month
break of depressive symptoms between episodes. The group
consisted of 21 (3.8%) patients who suffered current Insulin-
Dependent Diabetes Mellitus (IDDM) and 533 (96.2%) without
IDDM. Two other somatic illnesses and their relation with
depressive recurrence were studied by Wells et al. [24] however we
only used the information on the IDDM group while this was the
only current chronic somatic illness mentioned.
Study 2: The study of Gerrits, van Oppen, van Marwijk, van
der Horst and Penninx [26] is a cohort study (ages 18–65 years)
that consisted of 1209 adult participants with a current depression
or anxiety diagnosis as assessed by using the Composite
International Diagnostic Interview (CIDI) [27], based on DSM-
IV criteria [14], followed across two years. Only the information
on depression recurrence was used (received through personal
communication with the authors) which resulted in data on 715
patients with depression. A total of 318 patients (44.5%) had one
or more of the following chronic somatic diseases: cardio-
metabolic, respiratory, musculoskeletal, digestive, neurological,
endocrine and cancer.
Study 3: Kovacs, Obrosky, Goldston, and Bonar [28] included
54 children (ages 8–13 years) in their longitudinal follow-up study.
There were 24 children (44.4%) with current IDDM and 30
children (55.6%) with no other somatic disorders from the same
children’s hospital. MDD was assessed with the semi structured
Interview Schedule for Children and Adolescents (ISCA) [29].
The control subjects without somatic co-morbidity and a first
MDE were balanced for age of onset of first MDD, other co-
morbidities and basic characteristics. Of the 24 participants with
co-morbid IDDM, six (25%) already suffered from a major
psychiatric disorder (i.e. n = 4 with anxiety disorder, n = 1 conduct
disorder and n= 1 with functional enuresis). The follow-up period
was almost ten years (mean of 9.9 years). Recovery was defined as
not fulfilling criteria for MDE, i.e. the absence of symptoms or the
presence of few subclinical symptoms, and persistence of this state
for at least two months. Of the participants with IDDM, 21
(87.5%) recovered from a first episode as for 29 (96.7%) of the
control group.
Study 4: Hardeveld, Spijker, De Graaf, Nolen and Beekman
[30] included 687 patients from the general population (ages
between 18–64 years). Of the total group, 331 patients (48.2%)
had a somatic disease, which was assessed by a questionnaire
including 31, mostly, chronic somatic illnesses during the past
12 months. To be included in the study, patients had to be in
partial or complete remission of MDD and/or dysthymia for at
least six months and the amount of months of being in remission
could differ between patients. Remission was defined as: not
meeting the full MDE criteria and was assessed at baseline by the
computerized version of the CIDI [27]. MDE recurrence was
assessed between baseline and three year follow-up. Recurrence
was defined as the return of a MDE after partial or complete
remission of at least six months. The authors provided us with the
absolute numbers of MDE recurrence for patients with and
without a somatic illness.
Information on the quality criteria for all four included studies is
presented in table 2.
Risk Ratios
In figure 2 an overview of the number of recurrences in both the
patients with and without somatic illness are presented and the
RR’s of the four studies at all the follow-up intervals are shown in a
forest plot.
As shown in table 1 the reported recurrence rates in Wells et al.
[24] are lower at the one year follow-up but higher at the two year
follow-up in the current IDDM group compared to the group
without IDDM (14.9% vs. 29.3% at one year follow-up; 36.0% vs.
27.8% at two year follow-up). The calculated RR at one year
follow-up is far below one, which might indicate less risk for
recurrence of depression in the IDDM patients (n = 21) in
comparison to the non-IDDM patients (n = 533). However at
two year follow-up there is a shift to a somewhat higher than one
RR, indicating more risk for depressive recurrence in the IDDM
patients compared to the non-IDDM patients. In the IDDM
group, the calculated RR’s at one-and two year follow-up are
based on recurrences of three and eight patients respectively. Also,
the fact that the 95% CI contains the score of one in both cases
leads us to conclude that there is no higher risk for two or more
depressive episodes for patients with co-morbid IDDM compared
to patients without co-morbid IDDM (RR=0.49, 95% CI, 0.17–
1.40; RR=1.37, 95% CI, 0.78–2.41).
Among the 715 participants in the study by Gerrits et al. [26],
57 (8.0%) of the participants who did not have a co-morbid
chronic somatic illness experienced a recurrence after remission
versus 43 participants (6.0%) who did have one or more co-morbid
chronic somatic illnesses. The RR of having one or more chronic
somatic illnesses was around one (RR=0.94, 95% CI, 0.65–1.36)
meaning that in this sample there was no higher risk of recurrence
after remission for patients with co-morbid chronic somatic
illnesses.
Kovacs et al. [28] found similar recurrence rates in the illness
group at one, -two -and 6.5 years of follow-up (respectively: 26%
in the somatic illness group versus 22% in the control group; 30%
in the somatic ill versus 32% in the control condition; 47% in both
the somatically ill and the control condition). RR’s range from
0.99–1.15, which again is around one and indicates that the
presence of co-morbid IDDM therefore did not seem to heighten
the risk of recurrence in this group at one-, two-, and 6.5 year
follow-up respectively (RR=1.15, 95% CI, 0.40–3.27; RR=1.07,
95% CI, 0.48–2.42; RR=0.99, 95% CI, 0.55–1.77).
In the study of Hardeveld et al. [30] 135 patients (19.7%)
experienced a recurrence. The median time to recurrence was six
years (SD=5.5). MDE recurrence rate was 21.1% for patients
with a somatic illness compared to 18.3% for patients without a
somatic illness. The RR of MDE recurrence was close to one
(RR=1.16, 95% CI, 0.86–1.57). This indicates that there is no
significant heightened risk for a depressive recurrence, between
baseline and three years of follow-up, for patients with a co-
morbid somatic illness in comparison to patients without a co-
morbid somatic illness.
Discussion
The aim of this systematic review was to determine whether
having a co-morbid chronic somatic illness in MDD predicts a
greater risk of depressive recurrence. Only four studies examined
recurrence in patients with- and without co-morbid chronic
Risk for Depressive Recurrence in Somatically Ill
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somatic illnesses. Surprisingly, there was no indication that co-
morbid somatic illness was associated with a greater risk for
recurrence.
Strengths and limitations
We applied broad search terms and inclusion criteria, and
acquired studies through three important databases, reference lists,
guidelines and experts in the field. This led to the identification of
a large number of articles that were reviewed in a systematic
fashion by multiple reviewers. Most studies failed to meet the
inclusion criteria, mainly because they did not include a reference
group without a somatic illness. Rather, these studies presented
results of depression and its course within a specific disease group
only. Presence of a reference group is crucial in order to draw
conclusions on the risk ratio for recurrence that is associated with
co-morbid somatic illness.
The included studies differed to a large extent in their
methodological characteristics. Therefore it was not appropriate
to do a meta-analysis and calculate a pooled risk ratio. The
included studies had methodological problems; the quality
assessment shows some of these limitations. Whereas baseline
depression was defined by DSM criteria in all four studies that was
not the case with respect to depressive recurrence at follow-up in
the study by Wells et al. [24]. Wells et al. [24] assessed the number
of patients with more than two depressive episodes during follow-
up. Episodes were defined as periods of depression separated by at
least two months of intervening remission as reported by the
patient; no DSM criteria were applied to each separate episode.
This is not in accordance with the other three studies that did
identify each separate episode of depression by applying DSM
criteria. Additionally, these episodes cannot be directly compared
to MDE recurrences as reported in Gerrits et al. [26], Kovacs
et al. [28] and Hardeveld et al. [30]. On the other hand, since
Wells et al. [24] reported exclusively more than two episodes
during follow-up, the actual rate of recurrences could have been
underestimated. Gerrits et al. [26] used a life chart assessment to
minimize the risk of missing possible recurrences [31]. Depressive
symptomatology fluctuates over time (1) and can be easily
Table 2. Quality assessment of the included studies according to a modified version of the Newcastle-Ottowa Quality Assessment
Scale for cohort studies.
Domain
Wells, Rogers, Burnam
& Camp (1993)
Gerrits, van Oppen, van
Marwijk, van der Horst
& Penninx (2013)
Kovacs, Goldston,
Obrosky & Drash (1997)
Hardeveld, Spijker,
De Graaf, Nolen &
Beekman (2012)
Representativeness of cohort * * - *
Selection of the non- exposed cohort * * ? *
Ascertainment of exposure - * * -
Comparability of groups with and without
somatic illness on basis of design or analysis
* * * *
Assessment of depression at baseline
(blinding demanded)
- ? - -
Assessment of depression at follow-up
(blinding demanded)
- - - -
Follow-up at least 6 months? * * * *
Adequacy of follow-up of cohorts ? ? ? -
Note, * = rated as meeting the quality criterion, - = rated as not meeting the quality criterion; ? = no information about quality criterion.
doi:10.1371/journal.pone.0057510.t002
Figure 2. Forest plot of the risk ratios of depressive recurrences with co-morbid chronic somatic illness for all four included studies
at their different measurement intervals.
doi:10.1371/journal.pone.0057510.g002
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overlooked if assessed only at fixed time points, like they did in
three out of the four studies [24], [28], [30]. In addition, there are
several differences between the studies that further complicated
drawing firm conclusions on the overall effect of somatic illness on
recurrence rates, such as, different follow-up times, received
treatment, type and assessment method of somatic illnesses,
depressive symptomatology at baseline, unequal sizes of somatic
illness and reference groups (the most unequal sample had 21
somatic ill patients versus 533 patients without somatic illness in
the study of Wells et al.) [24]. Also there were differences in the
choice and sizes of the reference groups (533, 397, 30 and 356
patients).
Implications
Current clinical guidelines, such as the APA [6] and the NICE
[4], [5], identified the group of MDD patients with co-morbid
chronic somatic illness as a ‘‘double trouble’’ group with poor
prognosis. Prolonged pharmacological maintenance treatment has
been recommended for these patients if they were treated with
antidepressants during the acute phase of their depressive episode.
Additional preventive psychological treatment was recommended
for those who received psychotherapy during acute treatment.
However, our review suggests that the number of studies that
could provide such evidence is very small and that those few
studies that are available provide no indication of any elevated risk
of recurrence among depressed patients with co-morbid somatic
illness. We therefore call for additional longitudinal studies about
the impact of co-morbid chronic somatic illness on the course of
depression. Apart from recurrence, other outcomes also are
potentially relevant, such as the quality of life, severity and
duration of episodes, hospitalization, sick leave from work and
persistence of depression. An interesting question might be
whether the prognosis of depression could deteriorate when
somatic illness progresses and if so, whether treatment of the
somatic illness can counter this process. Additionally, we need to
study whether maintenance pharmacotherapy’s, as well as
psychological interventions, are (equally) effective for this pre-
sumed high risk group regarding recurrence.
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